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Objective: Our previous study showed the potential beneﬁts of dehydroepiandrosterone (DHEA) sup-
plementation in women with a poor ovarian response (POR). Because the connection between cumulus
cells (CCs) and oocytes is a key step for oocyte maturation, we supposed that altered gene expression of
CCs in women with POR after DHEA supplementation might favor oocyte maturation.
Materials and methods: Women with POR treated with ﬂexible daily gonadotropin-releasing hormone
antagonist in vitro fertilization (IVF) cycles at The Reproductive Center in Kaohsiung Veterans General
Hospital, Kaohsiung, Taiwan between January 2013 and October 2013 were enrolled for this prospective
study. CCs were isolated during IVF before and after DHEA (CPH-Formulation, Oakdale, CA, USA) sup-
plementation. Nine genes of isolated CCs, including hyaluronan synthase (HAS2), versican (VCAN),
thrombospondin 1 (THBS1), runt-related transcription factor 2 (RUNX2), chromobox homolog 3 (CBX3),
tripartite motif-containing 28 (TRIM28), B-cell lymphoma 2 (BCL2), BCL2-associated X protein (BAX), and
ankyrin repeat domain 57 (ANKRD57), were compared.
Results: There was a signiﬁcant difference in the expression of genes in womenwith POR before and after
DHEA supplementation (all p < 0.05). All genes related to extracellular matrix (ECM) formation, including
HAS2, VCAN, and THBS1, were upregulated. By contrast, all genes involving cell development, differ-
entiation, and apoptosis regulation were downregulated. Unknown function gene ANKRD57 was also
downregulated after DHEA supplementation. Although expressions of both BCL2 and BAX were
decreased in women with POR after DHEA supplementation compared to those before treatment, the
ratio of BCL2 and BAX was signiﬁcantly increased in women with POR after DHEA supplementation,
suggesting that DHEA supplementation might activate the antiapoptosis process of CCs, which might be
beneﬁcial to the improvement of ovarian function in women with POR.
Conclusion: The study showed that DHEA therapy positively affected the gene expression of CCs in
women with POR, and provided evidence to support the positive effect of DHEA supplementation on
women with POR.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.s and Gynecology, National
2, Shih-Pai Road, Taipei 112,
cience, National Sun Yat-Sen
heng), phwang@vghtpe.gov.
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Diminished ovarian reserve (DOR) and/or poor ovarian
response (POR) is a tough and challenging issue encountered
during assisted reproductive technology (ART). The Cochraneby Elsevier Taiwan LLC. All rights reserved.
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and/or POR) concluded that there is still insufﬁcient evidence to
support the use of any one particular intervention either for pi-
tuitary downregulation, ovarian stimulation, or adjuvant therapy
to improve treatment outcomes in poor responders during in vitro
fertilization (IVF) cycles [1]. Because of poor IVF outcomes and
very low pregnancy rates (2e4%) [2], it may be suggested to
women with POR to receive an oocyte donation after failed IVF
cycles. However, this is not always acceptable because of ethical,
cultural, and political concerns. Therefore, scientists have tried
their best to develop strategies to help women with POR. Among
those strategies, dehydroepiandrosterone (DHEA), a precursor of
estradiol and testosterone, supplementation has been regarded as
a potential intervention to rejuvenate the ovarian condition and
improve ART outcomes for these women with POR [3e10]. How-
ever, why DHEA supplementation would help these women with
POR is still uncertain. Therefore, we thought it would be inter-
esting to know what happens in cumulus cells (CCs) after DHEA
supplementation.
CCs, somatic cells that surround the oocyte to form the
cumulus-oocyte complex (COC), play a central role in follicular
development with oocyte maturation, oocyte meiotic resump-
tion, and ovulation, and are mediated by bidirectional commu-
nication between CCs and the oocyte through specialized gap
junctions [11e15]. Interruption of the connections between CCs
and the oocyte may deteriorate oocyte quality with a resultant
poor embryo development and worse pregnancy outcome [15].
Therefore, identifying the quality of oocytes and predicting the
IVF outcome is possible by investigating the gene expression of
these CCs [16e29]. The potential of CCs to serve as markers of
oocyte maturation and competence [16e22], embryo develop-
ment and quality [17e20,23e25], pregnancy outcome
[17,24,26e29], and live birth [26] has been highlighted by gene
study of CCs. Furthermore, the procedure used to isolate these
CCs does not interrupt IVF cycles, so it is considered as nonin-
vasive [16e29].
However, how many genes of CCs will be involved in oocyte
maturation and successful ovulation is yet to be determined. Since
interconnection between oocytes and surrounding CCs is a critical
step for oocyte maturation and successful ovulation, genes of CCs
that are involved in extracellular matrix (ECM) formation, cell
development, differentiation, and apoptosis [17e19,23,26,30e41]
might be good candidates to explore the possible mechanisms
that allow for DHEA supplementation to enhance the ovarian
response in women with POR. Therefore, the focus of our current
study was the expression of nine genes of CCs in IVF cycles that
had been validated as playing important roles in the above-
mentioned function, except one [17e19,23,26,30e42]. We sup-
posed that these genes of CCs might be signiﬁcantly different
before and after DHEA supplementation. Three of the nine genes
that were involved in ECM formation, namely, hyaluronan syn-
thase (HAS2) [18,23,30], versican (VCAN) [17,19,26,31], and
thrombospondin 1 (THBS1) [32,33], were investigated. In addition,
three genes regulating cell development and differentiation,
namely, runt-related transcription factor 2 (RUNX2) [34,35],
chromobox homolog 3 (CBX3) [36,37], and tripartite motif-
containing 28 (TRIM28) [26,38] were also explored. Finally,
genes controlling apoptosis, such as B-cell lymphoma 2 (BCL2)
[39,40] and BCL2-associated X protein (BAX) [39,41] were studied.
We also studied one gene whose function is still unknown e
ankyrin repeat domain 57 (ANKRD57) [42]. The aim of the current
study was to explore the changes in these genes before and after
DHEA supplementation and to provide molecular evidence to
support the potential beneﬁts of DHEA supplementation in
women with POR.Materials and methods
Patients and design
This prospective study received Institutional Review Board
approval from the Committee for Human Research at Kaohsiung
Veterans General Hospital, Kaohsiung, Taiwan, with the identiﬁer
VGHKS13-CT11-17, and was registered at ClinicalTrials.gov with the
identiﬁer NCT02150330. All participating women were fully coun-
seled, and their written consent was obtained.Women treatedwith
IVF cycles at The Reproductive Center in Kaohsiung Veterans
General Hospital between January 2013 and October 2013 were
enrolled into the study. The following clinical situations led to
exclusion from the study: (1) ovarian cystectomy; (2) oophorec-
tomy; (3) exposure to cytotoxic or pelvic irradiation for malig-
nancy; or (4) taking herbal drugs or other hormonal agents.
Womenwith POR had tomeet Bologna poor responder criteria [43].
In order that the study population might be more homogeneous,
enrolled participants had to fulﬁll the following criteria: (1) serum
follicle-stimulating hormone (FSH) > 15 nIU/L, or serum anti-
Müllerian hormone (AMH) < 1 ng/mL; (2) abnormally low antral
follicle counts (AFC) < 4 on Day 2 of their menstrual cycle; and (3),
of importance, an unsuccessful ﬂexible daily gonadotropin
releasing hormone (GnRH) antagonist IVF cycle followed by DHEA
supplementation (CPH-Formulation, Oakdale, CA, USA) [10]. The
detailed IVF protocols can easily be found [10,44].
CCs collection
After oocyte retrieval, CCs were obtained from women with
POR before and after DHEA supplementation. The protocol for
isolation of CCs has been described in detail [45,46]. In brief, the
dispersed cells were transferred to a 15 mL centrifugation tube
containing 4 mL of Histopaque 1077 (Sigma Chemical, St. Louis,
MO, USA). Human luteinized CCs were separated from red blood
cells by centrifugation at 600g for 10 minutes. CCs formed a thin
layer between the Histopaque and the medium. Cells were
removed and placed in a new centrifugation tube and washed
using IVF medium, with centrifugation at 600g for 10 minutes. The
supernatant was discharged and the CCs were placed in at 80C
for RNA extraction.
Gene study
In our original design, a total of 24 genes, involving ECM for-
mation, cell development, cell differentiation, apoptosis, and other
uncertain functions in CCs were investigated. We found that 18 of
the 24 genes of CCs showed signiﬁcant changes. Since we could not
validate half of these genes (9 genes, data not shown), which were
signiﬁcantly altered after DHEA supplementation, and another six
genes (data not shown), which failed to show any signiﬁcant
change before and after DHEA supplementation, we did not further
test these 15 genes to explore their potential role in oocyte matu-
ration and/or ovulation (data not shown). However, we investi-
gated the remaining nine genes (Table 1), and the related primers
(Table 2). Total RNA was extracted from tissue specimens using the
acid-phenol guanidiummethod [47e50]. Brieﬂy,1 mL of TRIzol was
added to the CCs. The mixture was pipetted to mix and allowed to
sit for 5 minutes at room temperature. Chloroform (0.2 mL) was
added, mixed, and allowed to incubate at room temperature for
10minutes. Themixture was centrifuged at 12,000g for 20minutes,
and the supernatant was transferred to a fresh tube. Isopropanol
(0.5 mL) was added, mixed, and incubated for 10 minutes at room
temperature. The solution was centrifuged at 12,000g for 30 mi-
nutes, and the RNA was puriﬁed as above. The pellet was washed
Table 1
Nine genes of cumulus cells and their functions.
Gene ID (name) Known function Relevance for ART Refs
HAS2 (hyaluronan synthase) Extracellular matrix formation Extracellular matrix modeling or remodeling
is essential for ovulation and fertilization
[18,23,30]
VCAN (versican) Component of extracellular matrix Extracellular matrix modeling or remodeling is
essential for ovulation and fertilization
[17,19,26,31]
THBS1 (thrombospondin 1) Component of extracellular matrix Promotion of granulosa cell growth and maturation [32,33]
RUNX2 (runt-related transcription factor 2) Regulation of cell differentiation As a transcriptional repressor in luteinizing
granulosa cell and regulation of luteal functions
[34,35]
CBX3 (chromobox homolog 3) Regulation of cell differentiation Male germ cell survival and spermatogenesis [36,37]
TRIM28 (tripartite motif-containing 28) Gene transcription co-repressor and DNA repair Delayed oocyte maturation [26,38]
BCL2 (B-cell lymphoma 2) Antiapoptosis Involvement in oocyte development and function [39,40]
BAX (BCL2-associated X protein) Promotion of apoptosis Involvement in oocyte development and function [39,41]
ANKRD57 (ankyrin repeat domain 57) Unknown Unknown [42]
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(DEPC)-treated water, and stored at 80C. The quality of the RNA
samples was determined by electrophoresis through agarose gels
and staining with ethidium bromide. The 18S and 28S RNA bands
were visualized under UV light.
RNA was reverse transcribed in a ﬁnal volume of 20 mL con-
taining 1  reverse transcriptase buffer [500 mM each deoxyri-
bonucleotide (dNTP), 3 mM MgCl2, 75 mM KCl, and 50 mM Tris-
HCl (pH 8.3)], 10 units of RNasin RNase inhibitor (Promega,
Madison, WI, USA), 10 mM DTT, 50 units of Superscript II RNase H-
reverse transcriptase (Life Technologies, Inc., Gaithersburg, MD,
USA), 1.5 mM random hexamers (Pharmacia, Uppsala, Sweden),
and 1 mg total RNA. The samples were incubated at 20C for 10
minutes and at 42C for 30 minutes, and reverse transcriptase was
inactivated by heating at 99C for 5 minutes and cooling at 5C for
5 minutes.
All quantitative real-time polymerase chain reactions
(quantRT-PCR) were performed using an ABI Prism 7700 Sequence
Detection System (Perkin-Elmer Applied Biosystems, Foster City,
CA, USA). PCR was performed using the SYBR Green PCR Core
Reagents kit (Perkin-Elmer Applied Biosystems). The thermal
cycling conditions comprised an initial denaturation step at 95C
for 10 minutes, and 40 cycles at 95C for 15 seconds, and 60C for
1 minute. Speciﬁc PCR ampliﬁcation products were detected by
the ﬂuorescent double-stranded DNA-binding dye, SYBR Green.
Experiments were performed with duplicates for each data point.
All of the samples with a coefﬁcient of variation for Ct value > 1%
were retested.Table 2
Primer sequences of nine genes of cumulus cells.
Gene IDa Forward (F) and reverse (R) primers (5 -3) Gene bank number
HAS2 F: TGCTTTTGACGCTGTATGTAGTTC
R: AGCACCATGTCATATTGTTGTCC
NM_005328
VCAN F: CAAGCATCCTGTCTCACGAA
R: CAACGGAAGTCATGCTCAAA
NM_001164098
THBS1 F: GCCTGCGCACCATTGTG
R: AGGCCGCCTCAGCTCATT
NM_003246
RUNX2 F: CCAACCCACGAATGCACTATC
R: TAGTGAGTGGTGGCGGACATAC
NM_001278478
CBX3 F: AATGTTGGAATCCCTGTTGC
R: GTTCTTCCTGGCTTTTGCTG
NM_007276
TRIM28 F: GAGCGTCCTGGCACTAACTC
R: ACCGTTTCACACCTGACACA
NM_005762
BCL2 F: GCAATTCCGCATTTAATTCATGG
R: GAAACAGGCCACGTAAAGCAAC
NM_000633
BAX F: GCTGTTGGGCTGGATCCAAG
R: TCAGCCCATCTTCTTCCAGA
NM_138763
ANKRD57 F: GAAAAAGGCCTCCCAGTACC
R: GGTCCCCTCCATCTTCTAGG
NM_023016
a Please refer to Table 1 for expansion of gene names.Statistical analysis
Gene expression ratios were log-transformed and proportions
were arc-transformed to ensure Gaussian distribution. Data anal-
ysis was performed using SPSS version 22.0 (SPSS Inc., Chicago, IL,
USA). Data was presented as the mean ± standard deviation. Sta-
tistical comparisons were performed using a 2-tailed Student t test.
A p value < 0.05 was considered to be statistically signiﬁcant.
Results
Clinical outcome
A total of 10 women with POR were enrolled into the analysis;
their detailed clinical data have been described previously [10]. In
brief, after DHEA treatment, there was a statistically signiﬁcant
decrease of Day 3 FSH and estradiol, from 14.4 ± 1.7 mIU/mL to
10.1 ± 0.7 mIU/mL and from 51.2 ± 6.3 pg/mL to 35.2 ± 4.2 pg/mL,
respectively (both p < 0.0001). AFC, from 2.8 ± 1.0 to 4.1 ± 1.2
(p < 0.05), and AMH, from 0.4 ± 0.2 ng/mL to 0.84 ± 0.2 ng/mL
(p < 0.001) were statistically signiﬁcantly increased. There was also
a signiﬁcant increase in the number of oocytes retrieved, fertilized
oocytes, Day 3 embryos, and transferred embryos after DHEA
supplementation (p < 0.01, p < 0.0001, p < 0.0001, and p < 0.01,
respectively). After DHEA supplementation, three patients ulti-
mately had a successful pregnancy, although this increase did not
achieve statistical signiﬁcance (p ¼ 0.065).
Changes of CCs gene expression
Genes involving ECM formation, such as HAS2, VCAN, and
THBS1, were compared in women with POR before and after DHEA
supplementation. In women with POR after DHEA supplementa-
tion, the genes related to ECM formation of CCs were statistically
signiﬁcantly upregulated compared to those before DHEA supple-
mentation (all p < 0.05; Fig. 1).
In the gene study in the second group, which was related to cell
development and differentiation regulation, we found that all three
genes, including RUNX2, CBX3, and TRIM28, were downregulated
after DHEA supplementation, and all achieved statistical signiﬁ-
cance (all p < 0.05).
For apoptosis regulation, two genes, such as BCL2 and BAX, were
investigated. We found that expressions of BCL-2 and BAX of CCs in
women with POR after DHEA supplementation were signiﬁcantly
lower than in women without POR before supplementation (both
p < 0.05). The genewith an unknown functione ANKRD57, showed
decreased expression after DHEA treatment (p < 0.05).
The ratio of BCL2 and BAX was signiﬁcantly increased after
DHEA supplementation (Fig. 2), suggesting that DHEA treatment
Fig. 1. Quantitative real-time polymerase chain reaction analysis of gene expression of cumulus cells in women with poor ovarian response before and after dehydroepiandros-
terone (DHEA) supplementation. (A) Hyaluronan synthase (HAS2) expression, (B) versican (VCAN) expression, (C) thrombospondin 1 (THBS1) expression, (D) runt-related tran-
scription factor 2 (RUNX2) expression, (E) chromobox homolog 3 (CBX3) expression, (F) tripartite motif-containing 28 (TRIM28) expression, (G) B-cell lymphoma 2 (BCL2)
expression, (H) BCL2-associated X protein (BAX) expression, and (I) ankyrin repeat domain 57 (ANKRD57) expression.
*Indicates a statistically signiﬁcant difference (p < 0.05).
Poor ¼ poor ovarian response.
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with POR.
Discussion
DHEA, an endogenous steroid that originates from the adrenal
zona reticularis and from ovarian theca cells [51], is a precursor of
estradiol and testosterone [52].
DHEA serves as a prohormone of the follicular ﬂuid testosterone
during ovarian induction with exogenous gonadotropins [53].
Androgen receptors were detected in the ovarian stroma and gran-
ulosa cells of the primordial follicles, and were more clearly seen in
primary follicles and more advanced-stage follicles [54e56]. With
an increasing level of androgen, DHEA supplementationmay rescue
atresic follicles, promote preantral follicle development [57,58],
suppress apoptosis [54], and increase FSH receptors expression [59]
and the level of insulin-like growth factor-I (IGF-1) [60]. However,
the exact mechanism of the beneﬁcial effects of DHEA therapy on
reproductive outcomes in women with POR remains unclear.
Further thorough research is expected to resolve the issue.Several studies have reported that DHEA supplementation had
beneﬁcial effects on ovarian response [3,10], ovarian reserve
[4,5,10], oocytes and embryo yield and quality [6,10], cumulus
pregnancy rate [7,10], and live birth rate [8], and also improved the
miscarriage rate [9] in women with POR. In our earlier study [10],
biochemical and ultrasound parameters (FSH, estradiol, AMH, and
AFC) and treatment outcomes (numbers of oocytes retrieved,
fertilized oocytes, Day 3 embryos, and transferred embryos) all
ameliorated signiﬁcantly following DHEA supplementation,
compared to the women with POR before DHEA therapy. Never-
theless, the increase in the pregnancy rate did not reach statistical
signiﬁcance (p ¼ 0.065) [10]. Therefore, DHEA supplementation
may rejuvenate the ovarian condition to improve reproductive
outcomes, but not restore the original condition.
CCs are specialized to sustain and nurture the developing oocyte
via transzonal projections that originate from CCs and terminate at
the oocyte plasma membrane [14]. During ovulation, ECM pro-
duction, known as cumulus expansion, which determines oocyte
maturation and fertilization, is initiated in the COC [13]. HAS2,
which is involved in ECM formation [30], has higher expression
Fig. 2. The ratio of B-cell lymphoma 2 (BCL2) expression and BCL2-associated X pro-
tein (BAX) expression was statistically signiﬁcantly increased in women with poor
ovarian response after dehydroepiandrosterone (DHEA) supplementation compared to
that in the women with poor ovarian response before DHEA treatment.
*Indicates a statistically signiﬁcant difference (p < 0.05).
Poor ¼ poor ovarian response.
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quality embryos [18,23]. VCAN, which is a major component of
the COC ECM [31], was signiﬁcantly correlated with oocyte matu-
rity [19], pregnancy prediction [17], and live birth [26]. THBS1,
which is an ECM glycoprotein [32], exerts an autocrine effect on
granulosa cell growth and maturation [33]. RUNX2, which is
induced by LH surge and has been shown to play a signiﬁcant role
in cell differentiation, is reported to act as a transcriptional
repressor in luteinizing granulosa cells and to regulate various as-
pects of luteal function [34,35]. CBX3, which is involved in epige-
netic regulation of both cell differentiation and cancer
development [37], is required for male germ cell survival and
spermatogenesis [36]. TRIM28, which is a corepressor of gene
transcription and plays a role in DNA repair [38], is associated with
delayed oocyte maturation in non-early cleavage embryos [25]
(Table 1). Several studies have demonstrated that the increased
incidence of CC apoptosis was negatively correlated to oocyte
maturation and quality, fertilization, embryo development, and
pregnancy outcomes [61e64]. BCL2, an antiapoptosis protein, can
prevent cells from undergoing apoptosis and maintain cell survival
by inhibiting the release of cytochrome C from mitochondria
[39,40]. Bax, a proapoptotic protein, promotes mitochondrial
damage and cell death directly through inducing the release of
cytochrome c from mitochondria [39,41]. The BCL2 family proteins
have been shown to be expressed in human ovarian granulosa cells,
and the BCL2/BAX ratio seems to be a determinant of the granulosa
cells apoptotic process [39]. However, ANKRD57 is poorly charac-
terized and has an unknown function (Table 1).
In our current study, a markedly increased expression of HAS2,
VCAN, and THBS1 was found in women with POR following DHEA
therapy, compared to that of the same population before treatment.
As such, DHEA may be supposed to have a beneﬁcial effect on
cumulus expansion, which is important for ovulation and fertil-
ization. DHEA treatment may lead to the reduction of transcrip-
tional suppression of several genes by diminishing the expression
of TRIM28 or RUNX2. The expression of both BCL2 and BAX was
signiﬁcantly decreased with DHEA treatment, but the BCL2/BAX
ratio was markedly elevated after treatment, compared to that
before treatment. As a result, DHEA may be able to inhibitgranulose cells or CCs apoptosis, which has been reported to have
negative effects on oocyte maturation and quality, fertilization,
embryo development, and pregnancy outcomes [61e64]. The
expression of ANKRD57 was nearly zero after DHEA treatment,
compared to that before treatment. ANKRD57 supposedly may be
regarded as a marker of poor oocyte quality. Nevertheless, further
in-depth research is required to support the result.
The strengths of the present studywere: (1) it was a prospective,
self-controlled study; and (2) themolecular signature of each of the
CCs was tested on 30 samples to ensure reliability. The limitations
of our study were (1) it had a small population size; (2) there were
no normal controls; (3) the titer of gene expression, for example,
HAS2, VCAN, THBS1, and BCL2, was rather low; (4) there are still
many genes beyond our current study that might be very important
for oocytematuration and contribute to successful ovulation, and of
most importance, these genes might be affected after DHEA sup-
plementation. For example, SDC4, an abbreviation for syndecan 4, is
a cell-surface heparan sulfate proteoglycan that regulates gastru-
lation, neural tube closure, and directed neural crest migration in
Xenopus development [65], but these genes were not totally
explored in the current study, suggesting that our proposed nine
genes might be only part of the genes that were signiﬁcantly
affected by DHEA supplementation, and that these unrevealed
genes might also be important contributors to the interconnection
between CCs and oocytes.
In conclusion, although the exact mechanisms of DHEA remain
elusive, DHEA supplementation did have beneﬁcial effects on
ovarian response, ovarian reserve, oocytes and embryo yield and
quality, the cumulus pregnancy rate, and the live birth rate in DOR
patients and could be a potential treatment prior to oocyte dona-
tion. Our study partially conﬁrmed the above results and showed
that DHEA supplementation positively affected the gene expression
of CCs, including promotion of ECM formation and inhibition of
apoptosis. However, large, multicenter, randomized controlled tri-
als and further basic studies are required to provide more infor-
mation on the effects of DHEA on women with POR.Conﬂicts of interest
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